HomeProductsBioactive CompoundsPI3K/Akt/mTOR PathwayPI3KGedatolisib
Chemical structure of CAS 1197160-78-3

Gedatolisib

CAS No.1197160-78-3
MDL No.MFCD16875679
MFC32H41N9O4
MW615.70
InChI KeyDWZAEMINVBZMHQ-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1197160-78-3
Product NameGedatolisib

Biological Targets

PIK3R1·PIK3CB·PIK3CG·PIK3CA·PIK3R2·

Associated Conditions

myelodysplastic syndrome·cancer·endometrial neoplasm·non-small cell lung carcinoma·acute myeloid leukemia·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.

Oncotarget • Vol. 7, Issue 37 • 2016
PMID: 27542212PMC: PMC5312272DOI: 10.18632/oncotarget.11318

PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.

The Journal of surgical research • Vol. 176, Issue 2 • 2012
PMID: 22261591DOI: 10.1016/j.jss.2011.10.045

Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.

Bioorganic & medicinal chemistry letters • Vol. 21, Issue 16 • 2011
PMID: 21763134DOI: 10.1016/j.bmcl.2011.06.063

Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 17, Issue 10 • 2011
PMID: 21325073DOI: 10.1158/1078-0432.CCR-10-1694

Documentation

Similar Products